AR069157A1 - Antagonista especifico para el factor 8 de crecimiento y diferenciacion (gdf8), polinucleotido que codifica los aminoacidos que comprenden el antagonista gdf8 , celula anfitriona y vector que comprenden el polinucleotido, celula anfitriona que comprende el vector, metodo para producir un antagonista - Google Patents

Antagonista especifico para el factor 8 de crecimiento y diferenciacion (gdf8), polinucleotido que codifica los aminoacidos que comprenden el antagonista gdf8 , celula anfitriona y vector que comprenden el polinucleotido, celula anfitriona que comprende el vector, metodo para producir un antagonista

Info

Publication number
AR069157A1
AR069157A1 ARP080104796A ARP080104796A AR069157A1 AR 069157 A1 AR069157 A1 AR 069157A1 AR P080104796 A ARP080104796 A AR P080104796A AR P080104796 A ARP080104796 A AR P080104796A AR 069157 A1 AR069157 A1 AR 069157A1
Authority
AR
Argentina
Prior art keywords
gdf8
understand
antagonist
polinucleotide
codifying
Prior art date
Application number
ARP080104796A
Other languages
English (en)
Inventor
Lioudmila Gennadievna Tchistiakova
Christopher John Corcoran
Edward Roland Lavallie
Riyez Karim
Lisa Anne Collins-Racie
John Adam Nowak
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR069157A1 publication Critical patent/AR069157A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Moléculas relacionadas con el factor 8 de crecimiento y diferenciacion (GDF8), en particular epítopos específicos para GDF8 y otros antagonistas específicos para GDF8 en particular anticuerpos anti-GDF8 o proteína de union de antígeno o fragmento del mismo, que puede inhibir la actividad CDF8 y la senal in vitro y/o in vivo. Y un inmunoensayo utilizado para detectar y cuantificar el GDF8. Y métodos para diagnosticar, prevenir, mejorar y tratar trastornos asociados a GDF8, por ejemplo, trastornos degenerativos del musculo, oseos y de metabolismo de insulina. Finalmente, composiciones farmacéuticas para el tratamiento de tales trastornos al utilizar los anticuerpos, polipéptidos, polinucleotidos y vectores.
ARP080104796A 2007-11-01 2008-10-31 Antagonista especifico para el factor 8 de crecimiento y diferenciacion (gdf8), polinucleotido que codifica los aminoacidos que comprenden el antagonista gdf8 , celula anfitriona y vector que comprenden el polinucleotido, celula anfitriona que comprende el vector, metodo para producir un antagonista AR069157A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US178307P 2007-11-01 2007-11-01

Publications (1)

Publication Number Publication Date
AR069157A1 true AR069157A1 (es) 2009-12-30

Family

ID=40303702

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104796A AR069157A1 (es) 2007-11-01 2008-10-31 Antagonista especifico para el factor 8 de crecimiento y diferenciacion (gdf8), polinucleotido que codifica los aminoacidos que comprenden el antagonista gdf8 , celula anfitriona y vector que comprenden el polinucleotido, celula anfitriona que comprende el vector, metodo para producir un antagonista

Country Status (19)

Country Link
US (4) US8415459B2 (es)
EP (2) EP2215118B1 (es)
JP (1) JP5756291B2 (es)
KR (1) KR20100074321A (es)
CN (1) CN101970487A (es)
AR (1) AR069157A1 (es)
AU (1) AU2008319265A1 (es)
CA (1) CA2704315C (es)
CO (1) CO6270358A2 (es)
ES (1) ES2514518T3 (es)
IL (1) IL205448A0 (es)
MX (1) MX2010004915A (es)
PA (1) PA8802601A1 (es)
PE (1) PE20091163A1 (es)
RU (1) RU2447084C2 (es)
SA (1) SA08290697B1 (es)
TW (1) TW200934510A (es)
WO (1) WO2009058346A1 (es)
ZA (1) ZA201003876B (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2332977T3 (en) * 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CA3045808C (en) 2005-11-23 2022-08-16 Acceleron Pharma, Inc. Activin-actriia antagonists and uses for promoting bone growth
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
CN104524548A (zh) * 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
ES2415666T3 (es) * 2007-02-01 2013-07-26 Acceleron Pharma, Inc. Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIa para uso en la prevención o el tratamiento de metástasis de cáncer de mama o pérdida ósea relacionada con el cáncer de mama
TW201907946A (zh) 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
EP2484372A1 (en) * 2007-02-09 2012-08-08 Acceleron Pharma, Inc. Activin-ActRIIa Antagonists and Uses for Promoting Bone Growth in Cancer Patients
CA2699936A1 (en) * 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
EP4238993A3 (en) 2008-04-11 2023-11-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2009158025A2 (en) * 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HRP20230761T1 (hr) 2008-08-14 2023-10-13 Acceleron Pharma Inc. Gdf zamke
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US8138142B2 (en) * 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
US8293881B2 (en) 2009-06-12 2012-10-23 Acceleron Pharma Inc. Isolated nucleic acid encoding a truncated ActRIIB fusion protein
KR20140092941A (ko) * 2009-06-26 2014-07-25 아틀라스 안티바디스 에이비 면역검출능의 개선
CN102781518A (zh) * 2009-09-09 2012-11-14 阿塞勒隆制药公司 Actriib拮抗剂及其给药和用途
WO2011056896A1 (en) * 2009-11-03 2011-05-12 Acceleron Pharma Inc. Methods for treating fatty liver disease
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
US8512950B2 (en) 2010-07-21 2013-08-20 Saint Louis University Biolayer interferometry measurement of biological targets
EP2606066A1 (en) * 2010-08-16 2013-06-26 Amgen Inc. Antibodies that bind myostatin, compositions and methods
EP2638065A4 (en) 2010-11-08 2014-04-09 Acceleron Pharma Inc ACTRIIA BINDING AGENTS AND USES THEREOF
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
WO2013074557A1 (en) 2011-11-14 2013-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
TWI641687B (zh) * 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
EP2861617A1 (en) * 2012-06-15 2015-04-22 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスFcγRII特異的Fc抗体
TWI697501B (zh) 2012-08-24 2020-07-01 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
CN104768969B (zh) 2012-09-13 2021-04-16 百时美施贵宝公司 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白
WO2014071158A1 (en) 2012-11-02 2014-05-08 Celgene Corporation Activin-actrii antagonists and uses for treating bone and other disorders
WO2014163101A1 (ja) 2013-04-02 2014-10-09 中外製薬株式会社 Fc領域改変体
EP3816625A1 (en) 2013-05-06 2021-05-05 Scholar Rock, Inc. Compositions and methods for growth factor modulation
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素a之抗體及其用途
EP2853898B1 (en) 2013-09-27 2017-01-04 Medizinische Hochschule Hannover Analysis of myostatin in serum
CA2951926C (en) 2014-06-13 2023-01-10 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP6706617B2 (ja) 2014-11-06 2020-06-10 スカラー ロック インコーポレイテッドScholar Rock,Inc. 抗プロ/潜在型−ミオスタチン抗体およびその使用
WO2016073906A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
MX2017006521A (es) * 2014-11-24 2017-08-09 Somalogic Inc Compuestos de acido nucleico para unirse al factor de diferenciacion de crecimiento 11.
ES2946160T3 (es) 2014-12-03 2023-07-13 Celgene Corp Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico
TWI808330B (zh) 2014-12-19 2023-07-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
WO2016120652A1 (en) * 2015-01-30 2016-08-04 Debreceni Egyetem Muscle differentiation
WO2016120647A2 (en) * 2015-01-30 2016-08-04 Debreceni Egyetem Muscle regeneration
TW202248212A (zh) 2015-02-05 2022-12-16 日商中外製藥股份有限公司 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
EP3283519A1 (en) 2015-04-15 2018-02-21 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
SG11201708351XA (en) 2015-04-22 2017-11-29 Alivegen Usa Inc Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
AU2016352967A1 (en) 2015-11-10 2018-06-21 Medimmune, Llc Binding molecules specific for ASCT2 and uses thereof
WO2017104783A1 (en) * 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3394098A4 (en) * 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
JP2019504064A (ja) 2016-01-08 2019-02-14 スカラー ロック インコーポレイテッドScholar Rock,Inc. 抗プロ/潜在型ミオスタチン抗体およびその使用方法
EP3402520A4 (en) * 2016-01-14 2019-01-02 BPS Bioscience, Inc. Anti-pd-1 antibodies and uses thereof
CN109071646A (zh) 2016-03-11 2018-12-21 供石公司 TGFβ1-结合免疫球蛋白及其用途
PT3368069T (pt) 2016-06-13 2020-11-11 Scholar Rock Inc Uso de inibidores da miostatina e terapias de combinação
MY193497A (en) * 2016-06-17 2022-10-17 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies and methods of use
CA2971303A1 (en) 2016-06-21 2017-12-21 Bamboo Therapeutics, Inc. Optimized mini-dystrophin genes and expression cassettes and their use
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8
ES2944357T3 (es) 2017-01-06 2023-06-20 Scholar Rock Inc Tratamiento de enfermedades metabólicas inhibiendo la activación de miostatina
EP3551658A1 (en) 2017-01-06 2019-10-16 Scholar Rock, Inc. Isoform-specific, context-permissive tgf 1 inhibitors and use thereof
MX2020008991A (es) 2018-03-01 2020-12-10 Regeneron Pharma Metodos para alterar la composicion corporal.
SI3677278T1 (sl) 2018-07-11 2022-01-31 Scholar Rock, Inc. Izoformno selektivni zaviralci TGFBETA1 in uporaba le-teh
CA3105988A1 (en) 2018-07-11 2020-01-16 Abhishek Datta High-affinity, isoform-selective tgf.beta.1 inhibitors and use thereof
EP3820896A1 (en) 2018-07-11 2021-05-19 Scholar Rock, Inc. TGFbeta1 INHIBITORS AND USE THEREOF
JP2022514262A (ja) 2018-12-17 2022-02-10 レビトープ リミテッド 双子型免疫細胞エンゲージャー
MX2021007394A (es) 2018-12-18 2021-07-15 Regeneron Pharma Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a.
CA3144864A1 (en) 2019-06-27 2020-12-30 Pfizer Inc. Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
JP2022543658A (ja) 2019-08-07 2022-10-13 アクアラン セラピューティクス コーポレーション 抗nampt抗体及びその用途
CA3167427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgfb inhibitors and use thereof
US20230050148A1 (en) 2020-01-11 2023-02-16 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2022261480A1 (en) * 2021-06-11 2022-12-15 The Regents Of The University Of California Heparan sulfate mimetics to improve glucose clearance
CN114181908B (zh) * 2021-07-23 2023-11-17 无锡傲锐东源生物科技有限公司 抗人s100b蛋白鼠单克隆抗体及其应用
WO2023168326A2 (en) * 2022-03-03 2023-09-07 The Brigham And Women´S Hospital, Inc. Humanized and affinity-matured anti-ceacam1 antibodies and methods of use
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction
US11802870B1 (en) * 2022-12-13 2023-10-31 Panazee Kinetic immunoassay systems and methods

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス セラム ラボラトリ−ズ コミツシヨン 抗原活性を有するアミノ酸配列
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988007089A1 (en) * 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
WO1990013327A1 (en) 1989-04-28 1990-11-15 Riker Laboratories, Inc. Dry powder inhalation device
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
ES2251721T3 (es) * 1994-07-08 2006-05-01 The Johns Hopkins University School Of Medicine Factor-11 de diferenciacion del crecimiento.
US5562332A (en) 1994-12-27 1996-10-08 Hss Industries, Inc. Lobby table for lockable boxes with handicapped shelf
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5695760A (en) 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
SE9502800D0 (sv) 1995-08-10 1995-08-10 Astra Ab Disposable inhaler
EP0869815A1 (en) 1995-09-21 1998-10-14 University Of Utah Research Foundation Targeting of conjugates of poly(ethylene glycol) and antibodies against glutamic acid decarboxylase to islet cells
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
NZ513642A (en) 1999-01-21 2004-02-27 Metamorphix Inc Growth differentiation factor inhibitors and uses therefor
KR100582967B1 (ko) 2000-09-13 2006-05-24 엔테그리스, 아이엔씨. 액체 여과 기기
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
PT1419179E (pt) 2001-08-10 2010-03-16 Univ Aberdeen Domínios de ligação de antigenes
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
JP4429729B2 (ja) 2002-02-21 2010-03-10 ワイス エルエルシー Gasp1;フォリスタチンドメイン含有タンパク質
WO2003072714A2 (en) * 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
EP1635870A2 (en) 2003-06-02 2006-03-22 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
CN1934266A (zh) * 2004-03-23 2007-03-21 伊莱利利公司 抗肌肉生长抑素抗体
WO2005094446A2 (en) * 2004-03-23 2005-10-13 Eli Lilly And Company Anti-myostatin antibodies
AU2005293752A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
JP2008537488A (ja) 2005-03-23 2008-09-18 ワイス Gdf−8モジュレート物質の検出
CA2601086A1 (en) * 2005-03-23 2006-10-12 Wyeth Detection of an immune response to gdf-8 modulating agents
MX2007013217A (es) * 2005-04-25 2008-03-11 Pfizer Anticuerpos contra miostatina.
CN103450359B (zh) 2005-08-19 2018-07-24 惠氏有限责任公司 抗gdf-8的拮抗剂抗体以及在als和其他gdf-8-相关病症治疗中的用途
EP1951756B1 (en) * 2005-10-06 2015-01-07 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
PT2066695E (pt) * 2006-09-05 2013-05-23 Lilly Co Eli Anticorpos anti-miostatina
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US8841340B2 (en) * 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound

Also Published As

Publication number Publication date
JP2011504096A (ja) 2011-02-03
JP5756291B2 (ja) 2015-07-29
ZA201003876B (en) 2011-04-28
PE20091163A1 (es) 2009-08-09
US9409981B2 (en) 2016-08-09
KR20100074321A (ko) 2010-07-01
CA2704315A1 (en) 2009-05-07
CA2704315C (en) 2016-05-24
EP2215118B1 (en) 2014-08-06
CN101970487A (zh) 2011-02-09
TW200934510A (en) 2009-08-16
US9850301B2 (en) 2017-12-26
US20090148436A1 (en) 2009-06-11
CO6270358A2 (es) 2011-04-20
EP2215118A1 (en) 2010-08-11
EP2805970A3 (en) 2015-03-04
MX2010004915A (es) 2010-05-27
RU2447084C2 (ru) 2012-04-10
SA08290697B1 (ar) 2012-02-12
US8415459B2 (en) 2013-04-09
US20170145084A1 (en) 2017-05-25
US20180265578A1 (en) 2018-09-20
ES2514518T3 (es) 2014-10-28
US20140023638A1 (en) 2014-01-23
AU2008319265A1 (en) 2009-05-07
IL205448A0 (en) 2010-12-30
EP2805970A2 (en) 2014-11-26
WO2009058346A1 (en) 2009-05-07
US10189896B2 (en) 2019-01-29
RU2010117018A (ru) 2011-12-10
PA8802601A1 (es) 2009-06-23

Similar Documents

Publication Publication Date Title
AR069157A1 (es) Antagonista especifico para el factor 8 de crecimiento y diferenciacion (gdf8), polinucleotido que codifica los aminoacidos que comprenden el antagonista gdf8 , celula anfitriona y vector que comprenden el polinucleotido, celula anfitriona que comprende el vector, metodo para producir un antagonista
Maslennikov et al. Membrane domain structures of three classes of histidine kinase receptors by cell-free expression and rapid NMR analysis
AR119683A1 (es) Anticuerpos y receptores de antígeno quimérico específicos para receptor huérfano 1 similar a receptor de tirosina quinasa (ror1)
Müller et al. Quantitative proteomics at different depths in human articular cartilage reveals unique patterns of protein distribution
EP2639301A3 (en) Polynucleotides encoding novel PCSK9 variants
EP3447074A3 (en) Human antigen binding proteins that bind to a complex comprising beta-klotho and an fgf receptor
Stephens et al. Different structural conformers of monomeric α-synuclein identified after lyophilizing and freezing
Stockwin et al. Proteomic analysis of plasma membrane from hypoxia-adapted malignant melanoma
Calamia et al. Metabolic labeling of chondrocytes for the quantitative analysis of the interleukin-1-beta-mediated modulation of their intracellular and extracellular proteomes
AU2024200758A1 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
AR067199A1 (es) Proteinas de union a antigenos que se unen a par-2
BRPI0922350A2 (pt) anticorpo humano, mólecula biespecífica,vetor de expressão, célula hospedeira eucariótica ou procariótoca recombinante, composição farmacêutica, uso do anticorpo ou da molécula biespecífica, métodos para inibir o desenvolvimento e/ou proliferação de uma célula tumoral que expressa o fator de tecido, para produzir um anticorpo, e para detectar a presença de fator de tecido em uma amostra, composição de diagnóstico, e, kit para detectar a presença de fator de tecido em uma amostra.
CL2012000886A1 (es) Polipeptido que comprende dos secuencias aminoacidas que permiten la union especifica al receptor para productos finales de glicosilacion avanzada (rpfga); uno o mas acidos nucleicos que codifican el polipeptido; celula; composicion; metodo para diagnosticar enfermedad o trastorno con rpfga.
FR2933773B1 (fr) Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
SG10201408073XA (en) Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
Gagnon et al. High-throughput in vivo screening of targeted molecular imaging agents
Pražienková et al. Prolactin-releasing peptide: physiological and pharmacological properties
Kakinen et al. Single-molecular heteroamyloidosis of human islet amyloid polypeptide
Brandhorst et al. Structure and function of a fungal adhesin that binds heparin and mimics thrombospondin-1 by blocking T cell activation and effector function
Murgia et al. Signatures of muscle disuse in spaceflight and bed rest revealed by single muscle fiber proteomics
BR112012011598A2 (pt) polipeptídeos de haemophilus parasuis e métodos de uso
ATE535546T1 (de) Humane monoklonale antikörper, die spezifisch an ifg-ii binden
Jia et al. Development of a sensitive microarray immunoassay for the quantitative analysis of neuropeptide Y
Ucci et al. Thyroid hormone protects from fasting-induced skeletal muscle atrophy by promoting metabolic adaptation
Xiao et al. A novel octapeptide derived from G protein-coupled receptor 124 improves cognitive function via pro-angiogenesis in a rat model of chronic cerebral hypoperfusion-induced vascular dementia

Legal Events

Date Code Title Description
FB Suspension of granting procedure